Cero Therapeutics Holdings, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
OQB
Isaiah Tibbs has filed a Schedule 13G, reporting beneficial ownership of 4.63% of Cero Therapeutics Holdings, Inc. common stock as of June 30, 2026.
OQB
Isaiah Tibbs has reported beneficial ownership of 8.67% of CERO Therapeutics Holdings, Inc.'s Common Stock in a Schedule 13G filing.
OQB
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a beneficial ownership of 4.99% in CERO Therapeutics Holdings, Inc.
OQB
Armistice Capital, LLC and its managing member Steven Boyd have disclosed a 9.99% passive beneficial ownership stake in CERO Therapeutics Holdings, Inc. as of March 31, 2025.